"Normal" thrombin generation.

We have investigated the influence of alterations in plasma coagulation factor levels between 50% and 150% of their mean values for prothrombin, factor X, factor XI, factor IX, factor VII, factor VIII, factor V, protein C, protein S, antithrombin III (AT-III), and tissue factor pathway inhibitor (TFPI) as well as combinations of extremes, eg, 50% anticoagulants and 150% procoagulants or 50% procoagulants and 150% anticoagulants in a synthetic "plasma" system. The reaction systems were constructed in vitro using purified, natural, and recombinant proteins and synthetic phospholipid vesicles or platelets with the reactions initiated by recombinant tissue factor (TF)-factor VIIa complex (5 pmol/L). To investigate the influence of the protein C system, soluble thrombomodulin (Tm) was also added to the reaction mixture. For the most extreme situations in which the essential plasma procoagulants (prothrombin, and factors X, IX, V, and VIII) and the stoichiometric anticoagulants (AT-III and TFPI) were collectively and inversely altered by 50%, a 28-fold difference in the total available thrombin generated was observed. Variations of most of these proteins 50% above and below the "normal" range, with the remainder at 100%, had only modest influences on the peak and total levels of thrombin generated. The dominant factors influencing thrombin generation were prothrombin and AT-III. When these 2 components were held at 100% and all other plasma procoagulants were reduced to 50%, there was a 60% reduction in the available thrombin generated. No increase in the thrombin generated was observed when the 150% level of all plasma procoagulants other than prothrombin was evaluated. When only prothrombin was raised to 150%, and all other factors were maintained at 100%, the thrombin generated increased by 71% to 121%. When AT-III was at 50% and all other constituents were at 100%, thrombin production was increased by 104% to 196%. The additions of protein C and protein S over the 50% to 150% ranges with Tm at 0.1 nmol/L concentration had limited influence on thrombin generation. Individual variations in factors VII, XI, and X concentrations had little effect on the duration of the initiation phase, the peak thrombin level achieved, or the available thrombin generated. Paradoxically, increases in factor IX concentration to 150% led to lowered thrombin generation, while decreases to 50% led to enhanced thrombin generation, most likely a consequence of factor IX as a competitive substrate with factor X for factor VIIa-TF. Reductions in factor V or factor VIII concentration led to prolongations of the initiation phase, while the reduction of TFPI to 50% led to shortening of this phase. However, none of these alterations led to significant changes in the available thrombin generated. Based on these data, one might surmise that increases in prothrombin and reductions in AT-III, within the normal range, would be potential risk factors for thrombosis and that algorithms that combine normal factor levels may be required to develop predictive tests for thrombosis.

[1]  A. Zivelin,et al.  Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors. , 1993, The Journal of clinical investigation.

[2]  P. Callas,et al.  The clinical spectrum of heterozygous protein C deficiency in a large New England kindred. , 1989, Blood.

[3]  K. Mann,et al.  The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. , 1983, The Journal of biological chemistry.

[4]  M. Makris,et al.  Co-inheritance of the 20210A Allele of the Prothrombin Gene Increases the Risk of Thrombosis in Subjects with Familial Thrombophilia , 1997, Thrombosis and Haemostasis.

[5]  K. Kurachi,et al.  Targeted inactivation of the coagulation factor IX gene causes hemophilia B in mice. , 1998, Blood.

[6]  W. Novotny Tissue Factor Pathway Inhibitor , 1994, Seminars in thrombosis and hemostasis.

[7]  M. Ogletree,et al.  Comparison of thrombin active site and exosite inhibitors and heparin in experimental models of arterial and venous thrombosis and bleeding. , 1993, The Journal of pharmacology and experimental therapeutics.

[8]  K. Mann,et al.  Coordinate binding of factor Va and factor Xa to the unstimulated platelet. , 1981, The Journal of biological chemistry.

[9]  S. Béguin,et al.  Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. , 1998, Arteriosclerosis, thrombosis, and vascular biology.

[10]  K. Mann,et al.  Activation of human prothrombin by human prothrombinase. Influence of factor Va on the reaction mechanism. , 1987, The Journal of biological chemistry.

[11]  J Jesty,et al.  Mathematical analysis of activation thresholds in enzyme-catalyzed positive feedbacks: application to the feedbacks of blood coagulation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Esmon,et al.  The natural anticoagulant protein S is decreased in male smokers. , 1991, American heart journal.

[13]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. II. A mathematical simulation. , 1994, Journal of Biological Chemistry.

[14]  M. Trimble,et al.  The antiphospholipid syndrome: prevalence among patients with stroke and transient ischemic attacks. , 1990, The American journal of medicine.

[15]  J. Levin,et al.  Familial Multiple Coagulation Factor Deficiencies , 1981, Seminars in thrombosis and hemostasis.

[16]  D. Ginsburg,et al.  Fatal haemorrhage and incomplete block to embryogenesis in mice lacking coagulation factor V , 1996, Nature.

[17]  L. Hoyer Medical progress : hemophilia A , 1994 .

[18]  K. Mann,et al.  Isolation of functional human coagulation factor V by using a hybridoma antibody. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[19]  R. Colman,et al.  Heterogeneity of human factor V deficiency. Evidence for the existence of antigen-positive variants. , 1983, The Journal of clinical investigation.

[20]  J. Mustard,et al.  Preparation of Suspensions of Washed Platelets from Humans , 1972, British journal of haematology.

[21]  P. Reitsma,et al.  A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. , 1996, Blood.

[22]  M. Woodward,et al.  EPIDEMIOLOGY OF COAGULATION FACTORS, INHIBITORS AND ACTIVATION MARKERS: THE THIRD GLASGOW MONICA SURVEY II. RELATIONSHIPS TO CARDIOVASCULAR RISK FACTORS AND PREVALENT CARDIOVASCULAR DISEASE , 1997, British journal of haematology.

[23]  P. Callas,et al.  An unknown genetic defect increases venous thrombosis risk, through interaction with protein C deficiency. , 1998, American journal of human genetics.

[24]  P. Carmeliet,et al.  Mice lacking factor VII develop normally but suffer fatal perinatal bleeding , 1997, Nature.

[25]  F. Ofosu,et al.  Maturation of the hemostatic system during childhood. , 1992, Blood.

[26]  S. Stone,et al.  Inhibitory mechanism of serpins. Interaction of thrombin with antithrombin and protease nexin 1. , 1995, Biochemistry.

[27]  Susan G. Brown,et al.  Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor , 1989, Nature.

[28]  K. Mann,et al.  Blood clotting in minimally altered whole blood. , 1996, Blood.

[29]  F R Rosendaal,et al.  Risk of Myocardial Infarction Associated With Factor V Leiden or Prothrombin Interaction of Coagulation Defects and Cardiovascular Risk Factors : Increased , 1998 .

[30]  C. Esmon,et al.  Recurrent venous thromboembolism in patients with a partial deficiency of protein S. , 1984, The New England journal of medicine.

[31]  K. Mann,et al.  A model for the tissue factor pathway to thrombin. I. An empirical study. , 1994, The Journal of biological chemistry.

[32]  M. Verstraete Modulating platelet function with selective thrombin inhibitors. , 1996, Haemostasis.

[33]  S. Özsoylu,et al.  Acquired factor IX deficiency. A report of two cases. , 1973 .

[34]  B. Brenner,et al.  Hereditary deficiency of all vitamin K‐dependent procoagulants and anticoagulants , 1990, British journal of haematology.

[35]  P. Reitsma,et al.  Homozygosity for a Novel Missense Mutation in the Prothrombin Gene Causing a Severe Bleeding Disorder , 1994, Thrombosis and Haemostasis.

[36]  M. Griffith,et al.  Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. , 1985, The Journal of biological chemistry.

[37]  R. Carrell,et al.  The incidence of dysfunctional antithrombin variants: four cases in 210 patients with thromboembolic disease , 1991, British journal of haematology.

[38]  M. Ragni,et al.  Factor VII deficiency , 1981, American journal of hematology.

[39]  K. Mann,et al.  "Clotspeed," a mathematical simulation of the functional properties of prothrombinase. , 1984, The Journal of biological chemistry.

[40]  F F Costa,et al.  Prevalence of the Prothrombin Gene Variant (nt20210A) in Venous Thrombosis and Arterial Disease , 1997, Thrombosis and Haemostasis.

[41]  K. Mann,et al.  Evaluation of the Initiation Phase of Blood Coagulation Using Ultrasensitive Assays for Serine Proteases* , 1997, The Journal of Biological Chemistry.

[42]  L. Mattsson,et al.  Haemostatic changes during continuous oestradiol-progestogen treatment of postmenopausal women. , 1991, British journal of obstetrics and gynaecology.

[43]  K. Mann,et al.  The regulation of clotting factors. , 1997, Critical reviews in eukaryotic gene expression.

[44]  S. Rapaport,et al.  A simplified procedure for purification of human prothrombin, factor IX and factor X. , 1981, Preparative biochemistry.

[45]  J. Griffin,et al.  Plasma protein S deficiency in familial thrombotic disease. , 1984, Blood.

[46]  R. Lundblad,et al.  Structure and function of factor IX: defects in haemophilia B. , 1985, Clinics in haematology.

[47]  B. Coller,et al.  Deficiency of Plasma Protein S, Protein C, or Antithrombin III and Arterial Thrombosis , 1987, Arteriosclerosis.

[48]  C. Mcmillan,et al.  Congenital combined deficiency of coagulation factors II, VII, IX and X. Report of a case. , 1966, The New England journal of medicine.

[49]  T. Perneger,et al.  Superficial Vein Thrombosis of Lower Limbs: Influence of Factor V Leiden, Factor II G20210A and Overweight , 1998, Thrombosis and Haemostasis.

[50]  H. Niessner,et al.  Coagulation Abnormalities in Liver Disease , 2008, Seminars in thrombosis and hemostasis.

[51]  E. Beltrami,et al.  Mathematical analysis of a proteolytic positive-feedback loop: dependence of lag time and enzyme yields on the initial conditions and kinetic parameters. , 1993, Biochemistry.

[52]  D. Tollefsen,et al.  Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma. , 1982, The Journal of biological chemistry.

[53]  M. Wardell,et al.  Inhibitory mechanism of serpins , 1997 .

[54]  P. Powers,et al.  Development of the human coagulation system in the full-term infant. , 1987, Blood.

[55]  J. Miletich,et al.  Absence of thrombosis in subjects with heterozygous protein C deficiency. , 1987, The New England journal of medicine.

[56]  Kenneth G. Mann,et al.  Inhibitory Mechanism of the Protein C Pathway on Tissue Factor-induced Thrombin Generation , 1997, The Journal of Biological Chemistry.

[57]  D. Tollefsen,et al.  Heparin cofactor II. , 1997, Advances in experimental medicine and biology.

[58]  K. Duffin,et al.  Heterogeneity of plasma tissue factor pathway inhibitor. , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[59]  K. Mann,et al.  Blood coagulation in hemophilia A and hemophilia C. , 1998, Blood.

[60]  Kenneth G. Mann,et al.  Regulation of Tissue Factor Initiated Thrombin Generation by the Stoichiometric Inhibitors Tissue Factor Pathway Inhibitor, Antithrombin-III, and Heparin Cofactor-II* , 1997, The Journal of Biological Chemistry.

[61]  B. Dahlbäck Purification of human vitamin K-dependent protein S and its limited proteolysis by thrombin. , 1983, The Biochemical journal.

[62]  D. Rosenthal Recurrent venous thromboembolism in patients with a partial deficiency of protein S: Comp PC, Esmon CT. N Engl J Med 1984;311:1525–1528 , 1985 .

[63]  G. Salvesen,et al.  Human plasma proteinase inhibitors. , 1983, Annual review of biochemistry.

[64]  K. Mann,et al.  Regulation of Prothrombinase Activity by Protein S , 1999, Thrombosis and Haemostasis.

[65]  C. Esmon,et al.  Protein S deficiency occurs in the nephrotic syndrome. , 1987, Annals of internal medicine.

[66]  L. Mattsson,et al.  Haemostatic changes during continuous oestradiolprogestogen treatment of postmenopausal women , 1990 .

[67]  R. Bertina,et al.  Congenital protein C deficiency and venous thromboembolism. A study of three Dutch families. , 1983, The New England journal of medicine.

[68]  Y Komiyama,et al.  Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. , 1990, Biochemistry.

[69]  P. Walsh Platelet coagulant activities and hemostasis: a hypothesis. , 1974, Blood.

[70]  K. Mann,et al.  Increased Tissue Factor-initiated Prothrombin Activation as a Result of the Arg506 → Gln Mutation in Factor VLEIDEN * , 1997, The Journal of Biological Chemistry.

[71]  J. T. ten Cate,et al.  Clinical applications of new antithrombotic agents , 1996, Annals of Hematology.